Best Routine Chlamydia Screening in Kathmandu Annual screening for sexually active adults — catch infection early

Overview: Routine Chlamydia Screening

Routine chlamydia screening means testing for chlamydia at regular intervals — typically annually — even when you have no symptoms. This is preventive medicine at its most effective: detecting asymptomatic infection before it causes pelvic inflammatory disease, infertility, or other complications. Because most chlamydia infections cause no symptoms, routine screening is the only reliable way to know your status.

The CDC recommends annual chlamydia screening for all sexually active women under 25, and for women 25 and older with risk factors such as new or multiple partners, inconsistent condom use, or a partner with a known STD. Men who have sex with men should screen every 3–6 months at exposed sites. Anyone diagnosed with another STD should also be tested for chlamydia.

Routine screening is not just for high-risk individuals — it is good preventive health practice for all sexually active adults. A simple urine NAAT test, repeated annually, provides peace of mind and catches infection early when treatment is simplest. For couples in monogamous relationships, mutual testing before unprotected sex and periodic screening provides additional protection.

At Thamel Clinic, routine chlamydia screening uses NAAT urine testing — the gold standard molecular test — with results available within hours to a day. Screening can be combined with other STD tests for comprehensive sexual health monitoring, and home sample collection is available for patients who prefer testing at home.

Why Routine Chlamydia Screening Matters

Chlamydia is called the "silent epidemic" because most infections cause no symptoms — up to 70% of infected women and about half of infected men feel completely normal. Without routine screening, these infections persist for months or years, silently damaging reproductive organs and spreading to partners.

The consequences of undetected chlamydia are serious. In women, untreated infection ascends to the uterus and fallopian tubes, causing pelvic inflammatory disease (PID), tubal scarring, chronic pelvic pain, and infertility. In men, it causes epididymitis and urethritis. In pregnant women, it increases preterm delivery risk and can infect the newborn.

Routine screening interrupts this silent progression. A simple annual urine test detects infection before symptoms or complications develop, allowing treatment with a short course of antibiotics that cures the infection completely. This is preventive medicine at its most cost-effective — a Rs. 1,500–2,500 test prevents infertility, chronic pain, and healthcare costs far exceeding the screening expense.

• Silent infection — most chlamydia causes no symptoms; screening is the only way to know.
• Prevents PID — early detection prevents pelvic inflammatory disease and its complications.
• Protects fertility — treating before tubal damage preserves reproductive health.
• Prevents transmission — detecting and treating prevents spread to partners.
• Cost-effective — screening is far cheaper than treating complications.
• Simple and quick — urine NAAT takes minutes, results within a day.

Who Needs Routine Chlamydia Screening?

The CDC recommends annual chlamydia screening for all sexually active women under 25 — the age group with the highest infection rates. Women 25 and older should screen annually if they have risk factors: new or multiple partners, inconsistent condom use, a partner with a known STD, or sex work. These recommendations apply regardless of symptoms.

Men who have sex with men should screen every 3–6 months at exposed sites (urethra, rectum, throat) because of higher infection risk. Anyone diagnosed with another STD should also be tested for chlamydia because coinfection is common. People with a new partner or after unprotected sex should test after the 1–2 week window period.

In Nepal, where routine screening is not yet standard practice, preventive chlamydia screening is valuable for all sexually active adults — especially young adults, university students, migrant workers, and anyone with new or multiple partners. Women planning pregnancy should screen before conception to protect fertility.

• Sexually active women under 25 — annual screening recommended.
• Women 25+ with risk factors — new/multiple partners, inconsistent condoms, partner with STD.
• Men who have sex with men — every 3–6 months at exposed sites.
• Anyone with another STD diagnosis — test for chlamydia too.
• New or non-monogamous partners — test after 1–2 week window period.
• Women planning pregnancy — screen before conception.
• All sexually active adults — routine screening is good preventive health.

How Routine Chlamydia Screening Works

Routine chlamydia screening uses NAAT (nucleic acid amplification testing) — the gold standard molecular test that detects the bacterium's genetic material directly. For most patients, a simple urine sample is sufficient — the first part of the urine stream contains enough organism material for accurate detection.

For women, cervical or vaginal swabs can also be used, and rectal or throat swabs are taken if those sites were exposed. For men who have sex with men, site-specific testing at all exposed sites is recommended because urine testing only covers genital infection.

The window period for chlamydia NAAT is approximately 1–2 weeks after exposure — testing too soon can give false-negative results. For routine annual screening, timing relative to exposure is less critical because you are testing for existing infection, not recent exposure. Results are typically available within hours to 24 hours.

• NAAT urine test — first-catch urine sample, non-invasive, over 95% accurate.
• Cervical/vaginal swab — alternative for women when urine testing not possible.
• Rectal and throat swabs — for exposures at those sites.
• Window period — 1–2 weeks after exposure; annual screening tests existing infection.
• Results in hours to 24 hours at modern laboratories.
• No fasting or special preparation — avoid urinating for 1–2 hours before urine sample.

How Often Should You Screen?

For most sexually active adults, annual chlamydia screening is appropriate — once a year provides good protection against silent infection. Women under 25 should screen annually regardless of partner status because infection rates are highest in this age group. Women 25 and older should screen annually if they have risk factors.

More frequent screening may be needed for higher-risk individuals — men who have sex with men every 3–6 months, people with multiple partners or inconsistent condom use every 3–6 months, and anyone with a new partner after the window period. After treatment for chlamydia, retesting at 3 months is recommended to confirm cure and detect reinfection.

For couples in monogamous relationships, mutual testing before unprotected sex and periodic screening (annually or when circumstances change) provides good protection. If either partner has a new partner or unprotected exposure, both should test after the window period.

• Annual screening — recommended for most sexually active adults.
• Women under 25 — annual regardless of partner status.
• Higher-risk individuals — every 3–6 months for MSM, multiple partners, inconsistent condoms.
• After treatment — retest at 3 months to confirm cure and detect reinfection.
• New partner — test after 1–2 week window period.
• Couples — mutual testing before unprotected sex, periodic screening.

What Happens If Screening Is Positive?

A positive chlamydia test is not a crisis — it is a common, easily treatable infection. Treatment is a short course of antibiotics — typically azithromycin (single dose) or doxycycline (7-day course). Both are highly effective when taken as prescribed. Symptoms usually resolve within days, and the infection is cured completely.

Partner management is essential — all partners from the exposure period should be tested and treated, even if they have no symptoms. Untreated partners cause reinfection, which is why treating only one partner often leads to repeat infection. The clinic can help with partner notification discreetly.

Follow-up testing at 3 months is recommended to confirm cure and detect reinfection. This is especially important if partners were not treated or if the patient has ongoing risk. At Thamel Clinic, positive results trigger immediate confidential contact for treatment planning — no need to wait for an appointment.

• Simple treatment — azithromycin single dose or doxycycline 7-day course.
• Highly effective — cures infection completely when taken as prescribed.
• Partner treatment essential — all partners from exposure period should be tested and treated.
• Discreet notification — clinic can help notify partners without revealing identity.
• Follow-up at 3 months — confirms cure and detects reinfection.
• Abstain from sex — until treatment complete and partners treated.

Costs and Convenience

Routine chlamydia screening is affordable — NAAT urine testing costs Rs. 1,500–2,500 at Kathmandu private laboratories. When combined with other STD tests as a panel, costs are lower per test. A full STD panel covering chlamydia, gonorrhea, syphilis, HIV, and hepatitis B runs approximately Rs. 3,500–6,000.

At Thamel Clinic, routine screening can be combined with other health checks for comprehensive preventive care. Home sample collection is available for patients who prefer testing at home or hotel — a convenient option for busy professionals and those who value privacy.

The cost of screening is minimal compared to the cost of treating complications — pelvic inflammatory disease, infertility treatment, and chronic pain management cost far more than annual screening. Investing in routine screening is one of the most cost-effective health decisions a sexually active adult can make.

• Chlamydia NAAT urine test: Rs. 1,500–2,500.
• Combined chlamydia + gonorrhea: Rs. 2,500–4,000.
• Full STD panel: Rs. 3,500–6,000 covering multiple infections.
• Home sample collection: Rs. 500–1,000 additional for home/hotel testing.
• Treatment: Rs. 200–500 for antibiotics if positive.
• Follow-up retest: Rs. 1,500–2,500 at 3 months.

Routine Chlamydia Screening Services

Prices in NPR are indicative; confirm current rates when booking. All services are confidential.

Related Services & Guides